uniQure N.V (UQ1) - Cash Flow Conversion Efficiency
Based on the latest financial reports, uniQure N.V (UQ1) has a cash flow conversion efficiency ratio of -0.256x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-38.24 Million ≈ $-44.71 Million USD) by net assets (€149.34 Million ≈ $174.60 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see uniQure N.V market capitalisation for the company's overall valuation and market capitalisation.
uniQure N.V - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how uniQure N.V's cash flow conversion efficiency has evolved over time, based on yearly financial data.
uniQure N.V Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of uniQure N.V ranked by their cash flow conversion efficiency. Explore UQ1 cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Snowsky Salt Industry Group Co Ltd
SHG:600929
|
0.020x |
|
Energizer Holdings Inc
NYSE:ENR
|
0.040x |
|
Omnicell Inc
NASDAQ:OMCL
|
0.025x |
|
Anhui Hengyuan Coal Industry and Electricity Power Co Ltd
SHG:600971
|
0.013x |
|
Rolls-Royce Holdings PLC
LSE:RR
|
0.829x |
|
SYoung Group Co Ltd
SHE:300740
|
0.010x |
|
Liberty Global PLC Class C
NASDAQ:LBTYK
|
0.024x |
|
Suzhou Oriental Semiconductor Co. Ltd. A
SHG:688261
|
-0.008x |
Annual Cash Flow Conversion Efficiency for uniQure N.V (2016–2025)
The table below shows the annual cash flow conversion efficiency of uniQure N.V from 2016 to 2025. View current stock price of uniQure N.V for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €198.90 Million ≈ $232.54 Million |
€-177.96 Million ≈ $-208.06 Million |
-0.895x | -103.31% |
| 2024-12-31 | €-6.75 Million ≈ $-7.89 Million |
€-182.73 Million ≈ $-213.63 Million |
27.063x | +3951.28% |
| 2023-12-31 | €207.67 Million ≈ $242.79 Million |
€-145.93 Million ≈ $-170.61 Million |
-0.703x | -130.59% |
| 2022-12-31 | €476.01 Million ≈ $556.50 Million |
€-145.06 Million ≈ $-169.59 Million |
-0.305x | -163.05% |
| 2021-12-31 | €595.78 Million ≈ $696.52 Million |
€287.96 Million ≈ $336.65 Million |
0.483x | +187.44% |
| 2020-12-31 | €243.91 Million ≈ $285.15 Million |
€-134.83 Million ≈ $-157.63 Million |
-0.553x | -80.96% |
| 2019-12-31 | €323.06 Million ≈ $377.69 Million |
€-98.68 Million ≈ $-115.37 Million |
-0.305x | +27.85% |
| 2018-12-31 | €179.61 Million ≈ $209.98 Million |
€-76.04 Million ≈ $-88.90 Million |
-0.423x | +41.14% |
| 2017-12-31 | €89.36 Million ≈ $104.47 Million |
€-64.27 Million ≈ $-75.14 Million |
-0.719x | +36.60% |
| 2016-12-31 | €63.63 Million ≈ $74.39 Million |
€-72.19 Million ≈ $-84.40 Million |
-1.134x | -- |
About uniQure N.V
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. Th… Read more